On November 19, Uni Health (02211.HK) announced that on November 19, 2024, the seller (Heilongjiang Jintian Loving Pharmaceutical Distribution Co., Ltd.) (an indirectly wholly-owned subsidiary of the company), entered into an equity transfer agreement with the buyer (Huang Yanling). Accordingly, the seller has conditionally agreed to sell, and the buyer has conditionally agreed to acquire 43.78% equity of Jilin Jintian Uni Health Group Capsule Co., Ltd. owned by the target company, for a price of RMB 43 million, subject to the restrictions of the equity transfer agreement. After the completion of the sale, the company will no longer hold any equity in the target company.

The target company's business covers the production, sales, and research and development of hollow capsules, making it the leading capsule production enterprise in northeast China. As of the date of this announcement, the seller holds approximately 43.78% of the target company's equity, the buyer holds approximately 54.43%, and the remaining equity is held by an independent third party.

To strengthen the group's cash flow situation to meet the group's funding needs, the board of directors has resolved to proceed with the sale. In addition, the company believes that through the sale, it will be able to optimize and adjust its asset structure to increase asset liquidity, improve asset utilization efficiency, and gain certain benefits. Therefore, the board of directors believes that the sale is in the overall interest of the company and shareholders.